AAAAAA

   
Results: 1-25 | 26-49
Results: 1-25/49
INFLUENCE OF TREATMENT WITH ONAPRISTONE ON THE IGF-SYSTEM IN BREAST-CANCER PATIENTS
Authors: HELLE SI JONAT W GIURESCU M EKSE D HOLLY JMP LONNING PE
Citation: Si. Helle et al., INFLUENCE OF TREATMENT WITH ONAPRISTONE ON THE IGF-SYSTEM IN BREAST-CANCER PATIENTS, Journal of steroid biochemistry and molecular biology, 66(3), 1998, pp. 159-163
THE ZEBRA STUDY - AN OPEN RANDOMIZED TRIAL OF ZOLADEX VS CMF AS ADJUVANT THERAPY IN THE MANAGEMENT OF NODE-POSITIVE STAGE-II BREAST-CANCER IN PRE PERI-MENOPAUSAL WOMEN AGED 50 YEARS OR LESS/
Authors: KAUFMANN M JONAT W
Citation: M. Kaufmann et W. Jonat, THE ZEBRA STUDY - AN OPEN RANDOMIZED TRIAL OF ZOLADEX VS CMF AS ADJUVANT THERAPY IN THE MANAGEMENT OF NODE-POSITIVE STAGE-II BREAST-CANCER IN PRE PERI-MENOPAUSAL WOMEN AGED 50 YEARS OR LESS/, European journal of cancer, 34, 1998, pp. 79-79
A NEW STANDARD TREATMENT FOR ADVANCED PREMENOPAUSAL BREAST-CANCER - AMETAANALYSIS OF THE COMBINED HORMONAL AGENT TRIALISTS GROUP (CHAT)
Authors: KLIJN JGM BLAMEY RW BOCCARDO F TOMINAGA T JONAT W KAUFMANN M BEEX L MAURIAC L HOCTINBOES G DUCHATEAU L SYLVESTER R
Citation: Jgm. Klijn et al., A NEW STANDARD TREATMENT FOR ADVANCED PREMENOPAUSAL BREAST-CANCER - AMETAANALYSIS OF THE COMBINED HORMONAL AGENT TRIALISTS GROUP (CHAT), European journal of cancer, 34, 1998, pp. 405-405
COMPARISON OF DOXORUBICIN CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN/CYCLOPHOSPHAMIDE/TAMOXIFEN AND CMF-CHEMOTHERAPY VERSUS TAMOXIFEN IN NODE-POSITIVE BREAST-CANCER - AN UPDATE OF THE GERMAN ADJUVANT BREAST-CANCER GROUP (GABG) TRIAL/
Authors: KAUFMANN IM JONAT W VONMINCKWITZ G SCHMID H KLEINE W MELCHERT F ULMER MU STOSIEK U TRAMS G BALZER J CAFFIER H
Citation: Im. Kaufmann et al., COMPARISON OF DOXORUBICIN CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN/CYCLOPHOSPHAMIDE/TAMOXIFEN AND CMF-CHEMOTHERAPY VERSUS TAMOXIFEN IN NODE-POSITIVE BREAST-CANCER - AN UPDATE OF THE GERMAN ADJUVANT BREAST-CANCER GROUP (GABG) TRIAL/, European journal of cancer, 34, 1998, pp. 82-82
LOW MORBIDITY AND NO MORTALITY OF HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA AND MITOXANTRONE PLUS AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL SUPPORT FOR HIGH-RISK BREAST-CANCER PATIENTS
Authors: KROGER N KRUGER WH GIESEKING F JAENICKE F SCHULTZE W FUSS H MOBUS V KONIGSMANN M BERDEL WE SCHAFERECKERT K WANDT H METZNER B ILLIGER HJ FRICKHOFEN N WULF G WORMANN B KOLBE K HOSSFELD DK MAAS H JONAT W ZANDER AR
Citation: N. Kroger et al., LOW MORBIDITY AND NO MORTALITY OF HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA AND MITOXANTRONE PLUS AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL SUPPORT FOR HIGH-RISK BREAST-CANCER PATIENTS, European journal of cancer, 34, 1998, pp. 92-92
THE ZEBRA STUDY - ZOLADEX (GOSERELIN) VS CMF AS ADJUVANT THERAPY IN THE MANAGEMENT OF NODE-POSITIVE STAGE-II BREAST-CANCER IN PRE PERI-MENOPAUSAL WOMEN AGED 50 YEARS OR LESS/
Authors: JONAT W KAUFMANN M BLAMEY R SHELDON T
Citation: W. Jonat et al., THE ZEBRA STUDY - ZOLADEX (GOSERELIN) VS CMF AS ADJUVANT THERAPY IN THE MANAGEMENT OF NODE-POSITIVE STAGE-II BREAST-CANCER IN PRE PERI-MENOPAUSAL WOMEN AGED 50 YEARS OR LESS/, European journal of cancer, 34, 1998, pp. 107-107
INTACT PREGNANCY WITH COEXISTENT HYDATIDIFORM MOLE OF A 2ND PLACENTA
Authors: BONATZ G WEISNER D FRAHM SO LUTGKES J JONAT W
Citation: G. Bonatz et al., INTACT PREGNANCY WITH COEXISTENT HYDATIDIFORM MOLE OF A 2ND PLACENTA, Zeitschrift fur Geburtshilfe und Perinatologie, 202(5), 1998, pp. 212-213
VULVAR CARCINOMA - INFLAMMATORY CELL INFILTRATION AS A PROGNOSTIC FACTOR
Authors: MUNDHENKE C WEIKEL W KNAPSTEIN PG JONAT W
Citation: C. Mundhenke et al., VULVAR CARCINOMA - INFLAMMATORY CELL INFILTRATION AS A PROGNOSTIC FACTOR, Annals of oncology, 9, 1998, pp. 72-72
PROGNOSTIC INFLUENCES ON SURVIVAL IN PATIENTS WITH VULVAR CARCINOMA
Authors: MUNDHENKE C WEIKEL W KNAPSTEIN PG JONAT W
Citation: C. Mundhenke et al., PROGNOSTIC INFLUENCES ON SURVIVAL IN PATIENTS WITH VULVAR CARCINOMA, Annals of oncology, 9, 1998, pp. 125-125
CYCLOPHOSPHAMIDE THIOTEPA/MITOXANTRONE WITH AUTOLOGOUS STEM-CELL RESCUE FOR HIGH-RISK STAGE-II AND STAGE-III BREAST-CANCER/
Authors: KRUGER WH KROGER N KONIGMANN M BERDEL WE FUSS H SCHULTZE W GIESEKING F SCHAFERECKART K MOBUS V FRICKHOFEN N WANDT H ILLIGER HJ METZNER B KOLBE K WORMANN B TRUMPER L HUBER C MAASS H JONAT W ZANDER AR
Citation: Wh. Kruger et al., CYCLOPHOSPHAMIDE THIOTEPA/MITOXANTRONE WITH AUTOLOGOUS STEM-CELL RESCUE FOR HIGH-RISK STAGE-II AND STAGE-III BREAST-CANCER/, Bone marrow transplantation, 22, 1998, pp. 31-31
LOW TOXICITY OF HIGH-DOSE CTM FOLLOWED BY AUTOLOGOUS STEM-CELL REINFUSION FOR HIGH-RISK BREAST-CANCER
Authors: KRUGER WH KROGER N KOLBE K HUBER C GIESEKING F JANICKE F KONIGSMANN M BERDEL WE KERSCHGENS C MAYR AC SCHAFERECKERT K WANDT H SCHULTZE W FUSS H METZNER B ILLIGER HJ FRICKHOFEN N MOBUS V HOSSFELD DK JONAT W ZANDER AR
Citation: Wh. Kruger et al., LOW TOXICITY OF HIGH-DOSE CTM FOLLOWED BY AUTOLOGOUS STEM-CELL REINFUSION FOR HIGH-RISK BREAST-CANCER, Bone marrow transplantation, 21, 1998, pp. 221-221
POLYCHEMOTHERAPY FOR EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS
Authors: ABE O ABE R ENOMOTO K KIKUCHI K KOYAMA H NOMURA Y SAKAI K SUGIMACHI K TOMINAGA T UCHINO J YOSHIDA M BENRAADT J VANDEVELDE AO VANDONGEN JA VERMORKEN JB GIOKAS G LISSAIOS B HARVEY VJ HOLDAWAY TM KAY RG MASON BH COATES A FORBES JF FOCAN C LOBELLE JP GATES GD POWELL J DURAND M MAURIAC L BARTHOLOMEUS S PICCART MJ GELMAN RS HENDERSON IC SHAPIRO CL HANCOCK AK MASOOD MB PARKER D PRICE JJ JACKSON S RAGAZ J DELOZIER T MACELESECH J HAYBITTLE JL BERRY D BROADWATER G CIRRINCIONE C MUSS H NORTON L BAUM M HOUGHTON J RILEY D DENT DM GUDGEON CA HACKING A GORDON NH DAVIS HL ROMESTAING P LEHINGUE Y OWEN JR MEIER P HOWELL A RIBEIRO GC SWINDELL R ALBANO J DEOLIVEIRA CF GERVASIO H GORDILHO J CARSTENSEN B PALSHOF T JOHANSEN H KORZENIOWSKI S SKOLYSZEWSKI J PORTNOJ SM ANDERSEN KW AXELSSON CK BLICHERTTOFT M MOURIDSEN HT OVERGAARD M ROSE C CORCORAN N TRAMPISCH HJ COMIS RL DAVIDSON NE GRAY R ROBERT N TORMEY DC WOOD W CHETTY U FORREST P JACK W ROSSBACH J SYLVESTER RJ VANDEVELDE CJH CUNNINGHAM MP BONNETERRE J FUMOLEAU P NAMER M BASTERT G RAUSCHECKER H SAUER R SAUERBREI W SCHAUER A SCHUMACHER M DESCHRYVER A BELFIGLIO M MARI E NICOLUCCI A SCORPIGLIONE N YOSEF HMA MCARDLE CS SMITH DC LARA PC BOCCARDO F RUBAGOTTI A ERAZO A MEDINA JY IZUO M MORISHITA Y BENTLEY A DORAN Z FENTIMAN IS HAYWARD JL RUBENS RD KAUFMANN M JONAT W SCHEURLEN H VONFOURNIER D FOUNTZILAS G KLAFSTROM P BLOMQVIST C CUZICK J MARGREITER R CASTIGLIONE M CAVILLI F COLLINS J FORBES J GELBER RD GOLDHIRSCH A LINDTNER J PRICE KN RUDENSTAM CM SENN HJ BLISS JM CHILVERS CED COOMBES RC MARTY M BOROVIK R BRUFMAN G HAYAT H ROBINSON E WIGLER N PANNUTI F TAKASHIMA S YASUTOMI T SONOO H YAMASHITA J OGAWA M WELVAART K HUPPERETS PSGJ BONTE J TENGRUP I TENNVALLNITTBY L MARTIN P ROMAIN S INGLE JN SUMAN VJ BUZDAR AU SMITH T HAKES T WITTES R DELAHUERTA R SAINZ MG BONADONNA G DELVECCHIO M VALAGUSSA P VERONESI U DUBOIS JB BIANCO AR LIPPMAN ME PIERCE LJ SIMON R STEINBERG SM MYLES JD PATER JL PRITCHARD KI ANDERSON S BROWN A BRYANT J COSTANTINO J DIGNAM J FISHER B REDMOND C WIEAND S WOLMARK N JACKSON IM PALMER MK BENGTSSON NO LARSSON LG LYTHGOE JP KISSIN M HANNISDAL E VARHAUG JE NISSENMEYER R BLAMEY RW MITCHELL AK ROBERTSON JFR UEO H MATHE G MISSET JL ABUZAHRA HT CLARKE EA MCLAUGHLIN JR CLARK RM LEVINE M MORIMOTO K SAWA K TAKATSUKA Y GUNDERSEN S HAUERJENSEN M HOST H CROSSLEY E HARRIS A BEIGHTON A CLARKE M COLLINS R DAVIES C EVANS V GODWIN J GREAVES E HARWOOD C JACKSON D JAMES S LAU E MEAD G NAUGHTEN A PETO R TOOTH A RAMBERT P ASSELAIN B SALMON RJ VILCOQ JR ARRIAGADA R HILL C LAPLANCHE A LE MG SPIELMANN M COCCONI G DIBLASIO B CATALANO R CREECH RH BROCKSCHMIDT J COOPER MR ANDRYSEK O BARKMANOVA J FALKSON CI ABRAHAM M KLIJN JGM TREURNIETDONKER AD VANPUTTEN WLJ EASTON D POWLES TJ GAZET JC SEMIGLAZOV V DESHPANDE N DIMARTINO L DOUGLAS P LINDTNER A NOTTER G BRYANT AJS EWING GH KRUSHENKOSLOSKI JL GEORGE WD GOULD A STEWART HJ STRONER P MOLLER TR RYDEN S CARSTENSEN J HATSCHEK T SODERBERG M CARPENTER JT ALBAIN K CROWLEY J GREEN S MARTINO S OSBORNE CK RAVDIN PM RUTQVIST LE WALLGREN A HOLM LE THURLIMANN B BRENNER H HERCBERGS A YOSHIMOTO M DEBOER G PATERSON AHG MEAKIN JW PANZARELLA T NAJA A BAHI J REID M SPITTLE M SENANAYAKE F BERGH J HOLMBERG L SEVELDA P ZIELINSKY CC GNANT M JAKESZ R BUCHANAN RB CROSS M DUNN JA GILLESPIE WM KELLY K MORRISON JM LITTON A CHLEBOWSKI RT BEZWODA WR CAFFIER H
Citation: O. Abe et al., POLYCHEMOTHERAPY FOR EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS, Lancet, 352(9132), 1998, pp. 930-942
ANASTROZOLE VERSUS MEGESTROL-ACETATE IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST-CARCINOMA - RESULTS OF A SURVIVAL UPDATEBASED ON A COMBINED ANALYSIS OF DATA FROM 2 MATURE PHASE-III TRIALS
Authors: BUZDAR AU JONAT W HOWELL A JONES SE BLOMQVIST CP VOGEL CL EIERMANN W WOLTER JM STEINBERG M WEBSTER A LEE D
Citation: Au. Buzdar et al., ANASTROZOLE VERSUS MEGESTROL-ACETATE IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST-CARCINOMA - RESULTS OF A SURVIVAL UPDATEBASED ON A COMBINED ANALYSIS OF DATA FROM 2 MATURE PHASE-III TRIALS, Cancer, 83(6), 1998, pp. 1142-1152
LUTEINIZING-HORMONE-RELEASING HORMONE ANALOGS THE RATIONALE FOR ADJUVANT USE IN PREMENOPAUSAL WOMEN WITH EARLY BREAST-CANCER
Authors: JONAT W
Citation: W. Jonat, LUTEINIZING-HORMONE-RELEASING HORMONE ANALOGS THE RATIONALE FOR ADJUVANT USE IN PREMENOPAUSAL WOMEN WITH EARLY BREAST-CANCER, British Journal of Cancer, 78, 1998, pp. 5-8
TELOMERE SHORTENING IN UTERINE LEIOMYOMAS
Authors: BONATZ G FRAHM SO ANDREAS S HEIDORN K JONAT W PARWARESCH R
Citation: G. Bonatz et al., TELOMERE SHORTENING IN UTERINE LEIOMYOMAS, American journal of obstetrics and gynecology, 179(3), 1998, pp. 591-596
ARIMIDEX - A POTENT AND SELECTIVE AROMATASE INHIBITOR FOR THE TREATMENT OF ADVANCED BREAST-CANCER
Authors: BUZDAR AU JONAT W HOWELL A PLOURDE PV
Citation: Au. Buzdar et al., ARIMIDEX - A POTENT AND SELECTIVE AROMATASE INHIBITOR FOR THE TREATMENT OF ADVANCED BREAST-CANCER, Journal of steroid biochemistry and molecular biology, 61(3-6), 1997, pp. 145-149
ANASTROZOLE 1 MG PROVIDES A COST-EFFECTIVE SURVIVAL BENEFIT, COMPAREDWITH MEGESTROL-ACETATE, FOR PATIENTS TREATED FOR ADVANCED BREAST-CANCER
Authors: THOMPSON E DRUMMOND M HOWELL A JONAT W BROWN J
Citation: E. Thompson et al., ANASTROZOLE 1 MG PROVIDES A COST-EFFECTIVE SURVIVAL BENEFIT, COMPAREDWITH MEGESTROL-ACETATE, FOR PATIENTS TREATED FOR ADVANCED BREAST-CANCER, European journal of cancer, 33, 1997, pp. 27-27
TRANSCRIPTIONAL REGULATION OF PROTEASE-INHIBITOR MASPIN WITH TUMOR SUPPRESSOR-ACTIVITY IN BREAST-CANCER
Authors: MAASS N NAGASAKI K ZHANG M SAGER R JONAT W
Citation: N. Maass et al., TRANSCRIPTIONAL REGULATION OF PROTEASE-INHIBITOR MASPIN WITH TUMOR SUPPRESSOR-ACTIVITY IN BREAST-CANCER, European journal of cancer, 33, 1997, pp. 13-13
SIGNIFICANTLY IMPROVED SURVIVAL WITH ARIMIDEX (ANASTROZOLE (A)) COMPARED WITH MEGESTROL-ACETATE (MA) IN POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST-CANCER (ABC) - UPDATED RESULTS OF 2 RANDOMIZED TRIALS
Authors: JONAT W BUZDAR A HOWELL A WEBSTER A STRUTT K
Citation: W. Jonat et al., SIGNIFICANTLY IMPROVED SURVIVAL WITH ARIMIDEX (ANASTROZOLE (A)) COMPARED WITH MEGESTROL-ACETATE (MA) IN POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST-CANCER (ABC) - UPDATED RESULTS OF 2 RANDOMIZED TRIALS, European journal of cancer, 33, 1997, pp. 644-644
RELATED SYMPOSIA - CHEMOTHERAPY OF GYNECO LOGICAL CANCER WITH TAXOL -CHEMOTHERAPY OF GYNECOLOGICAL CANCER WITH PACLITAXEL (TAXOL)
Authors: MEERPOHL HG JONAT W
Citation: Hg. Meerpohl et W. Jonat, RELATED SYMPOSIA - CHEMOTHERAPY OF GYNECO LOGICAL CANCER WITH TAXOL -CHEMOTHERAPY OF GYNECOLOGICAL CANCER WITH PACLITAXEL (TAXOL), Archives of gynecology and obstetrics, 260(1-4), 1997, pp. 372-377
TRANSCRIPTIONAL REGULATION OF PROTEASE-INHIBITOR MASPIN IN BREAST EPITHELIAL-CELL AND BREAST CANCER-CELL LINES
Authors: MAASS N ZHANG M SAGER R JONAT W
Citation: N. Maass et al., TRANSCRIPTIONAL REGULATION OF PROTEASE-INHIBITOR MASPIN IN BREAST EPITHELIAL-CELL AND BREAST CANCER-CELL LINES, Tumordiagnostik & Therapie, 18(4), 1997, pp. 89-96
COMPARISON OF INTRACELLULAR TUMOR-MARKER CONCENTRATIONS IN DIFFERENT GYNECOLOGICAL TISSUES AND THEIR MALIGNANT-TUMORS
Authors: WESTHOF G ZIPLINSKY N ANASTASIADIS A GENT HJ JONAT W
Citation: G. Westhof et al., COMPARISON OF INTRACELLULAR TUMOR-MARKER CONCENTRATIONS IN DIFFERENT GYNECOLOGICAL TISSUES AND THEIR MALIGNANT-TUMORS, Tumordiagnostik & Therapie, 18(2), 1997, pp. 51-56
FETAL HEART-RATE (FHR) PATHOLOGY IN LABOR RELATED TO PRECEDING DOPPLER SONOGRAPHIC RESULTS OF THE UMBILICAL ARTERY AND FETAL AORTA IN APPROPRIATE AND SMALL-FOR-GESTATIONAL-AGE BABIES - A LONGITUDINAL ANALYSIS
Authors: BONATZ G SCHULZ V WEISNER D JONAT W
Citation: G. Bonatz et al., FETAL HEART-RATE (FHR) PATHOLOGY IN LABOR RELATED TO PRECEDING DOPPLER SONOGRAPHIC RESULTS OF THE UMBILICAL ARTERY AND FETAL AORTA IN APPROPRIATE AND SMALL-FOR-GESTATIONAL-AGE BABIES - A LONGITUDINAL ANALYSIS, Journal of perinatal medicine, 25(5), 1997, pp. 440-446
P53 IS A PERSISTENT AND PREDICTIVE MARKER IN ADVANCED OVARIAN CARCINOMAS - MULTIVARIATE-ANALYSIS INCLUDING COMPARISON WITH KI67 IMMUNOREACTIVITY
Authors: ROHLKE P MILDELANGOSCH K WEYLAND C PICHLMEIER U JONAT W LONING T
Citation: P. Rohlke et al., P53 IS A PERSISTENT AND PREDICTIVE MARKER IN ADVANCED OVARIAN CARCINOMAS - MULTIVARIATE-ANALYSIS INCLUDING COMPARISON WITH KI67 IMMUNOREACTIVITY, Journal of cancer research and clinical oncology, 123(9), 1997, pp. 496-501
ANASTROZOLE (ARIMIDEX(R)) - REALIZING THE NEED FOR AN ORAL SELECTIVE AROMATASE INHIBITOR - SATELLITE SYMPOSIUM HELD AT THE 21ST CONGRESS OFTHE EUROPEAN-SOCIETY-FOR-MEDICAL-ONCOLOGY, VIENNA, AUSTRIA, OCTOBER 1996 - INTRODUCTION
Authors: JONAT W KAUFMANN M
Citation: W. Jonat et M. Kaufmann, ANASTROZOLE (ARIMIDEX(R)) - REALIZING THE NEED FOR AN ORAL SELECTIVE AROMATASE INHIBITOR - SATELLITE SYMPOSIUM HELD AT THE 21ST CONGRESS OFTHE EUROPEAN-SOCIETY-FOR-MEDICAL-ONCOLOGY, VIENNA, AUSTRIA, OCTOBER 1996 - INTRODUCTION, Oncology, 54, 1997, pp. 1-1
Risultati: 1-25 | 26-49